Sirtuin activators: Designing molecules to extend life span

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 10-12, 2010, Pages 740-749

  Camins, Antoni ^a   Sureda, Francesc X ^b   Junyent, Felix ^a,b   Verdaguer, Ester ^a   Folch, Jaume ^b   Pelegri, Carme ^a   Vilaplana, Jordi ^a   Beas Zarate, Carlos ^c   Pallàs, Mercè ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Diabetes; Neurodegenerative diseases; Resveratrol; Sirtuin activators; Sirtuins

Indexed keywords

ENZYME ACTIVATOR; FREE RADICAL; RESVERATROL; SCAVENGER; SIRTUIN 1; SRT2104; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON CANCER; DRUG EFFECT; HOMEOSTASIS; HUMAN; LIFESPAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

AGING; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; ENZYME ACTIVATORS; HUMANS; NEURONS; SIRTUIN 1; STILBENES;

ANIMALIA; RODENTIA;

EID: 78649861860     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2010.06.005     Document Type: Review

References (104)

1. Kapoor V.K., Dureja J., Chadha R. Synthetic drugs with anti-ageing effects. Drug Discov. Today 2009, 14:899-904.
2. Pallàs M., Verdaguer E., Tajes M., Gutierrez-Cuesta J., Camins A. Modulation of sirtuins: new targets for antiageing. Recent Pat. CNS Drug Discov. 2008, 3:61-69.
3. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr. Med. Chem. 2006, 13:87-98.
4. li-Youcef N., Lagouge M., Froelich S., Koehl C., Schoonjans K., Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann. Med. 2007, 39:335-345.
5. Bastianetto S., Brouillette J., Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem. Res. 2007, 32:1720-1725.
6. Bastianetto S., Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol. Aging 2002, 23:891-897.
7. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
8. Hekimi S., Guarente L. Life-span extension in yeast. Science 2003, 299:1351-1355.
9. Fremont L. Biological effects of resveratrol. Life Sci. 2000, 66:663-673.
10. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273:793-798.
11. Borra M.T., Smith D.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
12. Denu J.M. The Sir 2 family of protein deacetylases. Curr. Opin. Chem. Biol. 2005, 9:431-440.
13. Kaeberlein M., McDonagh T., Heltweg B. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 2005, 280:17038-17045.
14. Kim E.J., Kho J.H., Kang M.R., Um S.J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell 2007, 28:277-290.
15. Kobayashi Y., Furukawa-Hibi Y., Chen C. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int. J. Mol. Med. 2005, 16:237-243.
16. Jang M., Cai L., Udeani G.O. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
17. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591.
18. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
19. Hekimi S., Guarente L. Genetics and the specificity of the aging process. Science 2003, 299:1351-1354.
20. Cantó C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab. 2009, 20:325-331.
21. Lin S.J., Kaeberlein M., Andalis A.A. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature 2002, 418:344-348.
22. Lin S.J., Ford E., Haigis M., Liszt G., Guarente L. Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev. 2004, 18:12-16.
23. Tang B.L. SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiol. Aging 2006, 27:501-505.
24. Balan V., Miller G.S., Kaplun L., Balan K., Chong Z.Z., Li F., Kaplun A., VanBerkum M.F., Arking R., Freeman D.C., Maiese K., Tzivion G. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J. Biol. Chem. 2008, 283:27810-27819.
25. Terzibasi E., Valenzano D.R., Cellerino A. The short-lived fish Nothobranchius furzeri as a new model system for aging studies. Exp. Gerontol. 2007, 42:81-89.
26. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
27. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16:296-300.
28. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W., Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
29. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 2004, 16:93-105.
30. Vaquero A. The conserved role of sirtuins in chromatin regulation. Int. J. Dev. Biol. 2009, 53:303-322.
31. Parseghian M.H., Newcomb R.L., Winokur S.T., Hamkalo B.A. The distribution of somatic H1 subtypes is non-random on active vs. inactive chromatin: distribution in human fetal fibroblasts. Chromosome Res. 2000, 8:405-424.
32. Parseghian M.H., Newcomb R.L., Hamkalo B.A. Distribution of somatic H1 subtypes is non-random on active vs. inactive chromatin II: distribution in human adult fibroblasts. J. Cell. Biochem. 2001, 83:643-659.
33. Dang W., Steffen K.K., Perry R., Dorsey J.A., Johnson F.B., Shilatifard A., Kaeberlein M., Kennedy B.K., Berger S.L. Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 2009, 459:802-807.
34. Westerheide S.D., Anckar J., Stevens S.M., Sistonen L., Morimoto R.L. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009, 323:1063-1066.
35. Lindner H., Sarg B., Grunicke H., Helliger W. Age-dependent deamidation of H1(0) histones in chromatin of mammalian tissues. J. Cancer Res. Clin. Oncol. 1999, 125:182-186.
36. Nemoto S., Fergusson M.M., Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 2005, 280:16456-16460.
37. Lagouge M., Argmann C., Gerhart-Hines Z. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
38. Guarente L. Mitochondria a nexus for aging, calorie restriction, and sirtuins?. Cell 2008, 132:171-176.
39. Tajes M., Gutierrez-Cuesta J., Ortuño-Sahagun D., Camins A., Pallàs M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J. Pineal Res. 2009, 47:228-237.
40. Aliev G., Obrenovich M.E., Reddy V.P., Shenk J.C., Moreira P.I., Nunomura A., Zhu X., Smith M.A., Perry G. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev. Med. Chem. 2008, 8:1395-1406.
41. Esiri M.M. Ageing and the brain. J. Pathol. 2007, 211:181-187.
42. Bradford F., Gupta S. A review of antioxidant and Alzheimer's disease. Ann. Clin. Psychiatry 2005, 37:269-286.
43. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
44. Fleury C., Mignotte B., Vayssiere J.L. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002, 84:131-141.
45. Mattson M.P. Dietary factors, hormesis and health. Ageing Res. Rev. 2008, 7:43-48.
46. Mattson M.P., Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci. 2006, 29:632-639.
47. Barger J.L., Kayo T., Vann J.M. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008, 3:e2264.
48. Terzibasi E., Lefrançois C., Domenici P., Hartmann N., Graf M., Cellerino A. Effects of dietary restriction on mortality and age-related phenotypes in the short-lived fish Nothobranchius furzeri. Aging Cell 2009, 8:88-99.
49. Wang F., Nguyen M., Qin F.X., Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007, 6:505-514.
50. Anselmi C.V., Malovini A., Roncarati R., Novelli V., Villa F., Condorelli G., Bellazzi R., Puca A.A. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res. 2009, 12:95-104.
51. Flachsbart F., Caliebe A., Kleindorp R., Blanché H., von Eller-Eberstein H., Nikolaus S., Schreiber S., Nebel A. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2700-2705.
52. Li Y., Wang W.J., Cao H., Lu J., Wu C., Hu F.Y., Guo J., Zhao L., Yang F., Zhang Y.X., Li W., Zheng G.Y., Cui H., Chen X., Zhu Z., He H., Dong B., Mo X., Zeng Y., Tian X.L. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Hum. Mol. Genet. 2010, 24:4897-4904.
53. Kennedy B.K., Kaeberlein M. Hot topics in aging research: protein translation. Aging Cell 2009, 8(8):617-623.
54. Wu P., Jiang C., Shen Q., Hu Y. Systematic gene expression profile of hypothalamus in calorie-restricted mice implicates the involvement of mTOR signaling in neuroprotective activity. Mech. Ageing Dev. 2009, 130:602-610.
55. Blagosklonny M.V. TOR-driven aging: speeding car without brakes. Cell Cycle 2009, 8:4055-4059.
56. Salminen A., Kaarniranta K. Regulation of the aging process by autophagy. Trends Mol. Med. 2009, 15:217-224.
57. Salminen A., Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell. Signal. 2009, 21:1356-1560.
58. Anekonda T.S., Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. 2006, 96:305-313.
59. Julien C., Tremblay C., Emond V., Lebbadi M., Salem N., Bennett D.A., Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2009, 68:48-58.
60. Patel N.V., Gordon M.N., Connor K.E., Good R.A., Engelman R.W., Mason J., Morgan D.G., Morgan T.E., Finch C.E. Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 2005, 26:995-1000.
61. Martin B., Mattson M.P., Maudsley S. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev. 2006, 5:332-353.
62. Qin W., Yang T., Ho L., Zhao Z. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 2006, 281:21745-21754.
63. Wang J., Ho L., Zhao Z., Seror I., Humala N., Dickstein D.L., Thiyagarajan M., Percival S.S., Talcott S.T., Pasinetti G.M. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006, 20:2313-2320.
64. Zhuang H., Kim Y.S., Koehler R.C., Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann. NY Acad. Sci. 2003, 993:276-286.
65. Jang J.H., Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 2003, 34:1100-1108.
66. Savaskan E., Olivieri G., Meier F., Seifritz E., Wirz-Justice A., Muller-Spahn F. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003, 49:380-383.
67. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280:37377-37382.
68. Vingtdeux V., Dreses-Werringloer U., Zhao H., Davies P., Marambaud P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008, 9:S6.
69. Jang M.H., Piao X.L., Kim J.M., Kwon S.W., Park J.H. Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis. Phytother. Res. 2008, 22:544-549.
70. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., Delalle I., Baur J.A., Sui G., Armour S.M., Puigserver P., Sinclair D.A., Tsai L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26:3169-3179.
71. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54:111-118.
72. Brundin P., Li J.Y., Holton J.L., Lindvall O., Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9:741-745.
73. Lu K.T., Ko M.C., Chen B.Y., Huang J.C., Hsieh C.W., Lee M.C., Chiou R.Y., Wung B.S., Peng C.H., Yang Y.L. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem. 2008, 56:6910-6913.
74. Blanchet J., Longpré F., Bureau G., Morissette M., DiPaolo T., Bronchti G., Martinoli M.G. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1243-1250.
75. Alvira D., Yeste-Velasco M., Folch J., Verdaguer E., Canudas A.M., Pallàs M., Camins A. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience 2007, 147:746-756.
76. Okawara M., Katsuki H., Kurimoto E., Shibata H., Kume T., Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol. 2007, 73:550-560.
77. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., Martelli G., Colombo L., Manzoni C., Salmona M., Caccia S., Negro A., Forloni G. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009, 110:1445-1456.
78. Long J., Gao H., Sun L., Liu J., Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res. 2009, 12:321-331.
79. Barber S.C., Shaw P.J. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010, 48:629-641.
80. Dion P.A., Daoud H., Rouleau G.A. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat. Rev. Genet. 2009, 10:769-782.
81. Barber S.C., Higginbottom A., Mead R.J., Barber S., Shaw P.J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med. 2009, 46:1127-1138.
82. Markus M.A., Morris B.J. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin. Interv. Aging 2008, 3:331-339.
83. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Paul D., Maulik N. Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J. Agric. Food Chem. 2008, 56:9692-9698.
84. Ungvari Z., Labinskyy N., Mukhopadhyay P., Pinto J.T., Bagi Z., Ballabh P., Zhang C., Pacher P., Csiszar A. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1876-H1881.
85. Csiszar A., Labinskyy N., Pinto J.T., Ballabh P., Zhang H., Losonczy G., Pearson K., de Cabo R., Pacher P., Zhang C., Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H13-H20.
86. Wallerath T., Deckert G., Ternes T. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106:1652-1658.
87. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
88. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8:347-358.
89. Aubin M.C., Lajoie C., Clément R., Gosselin H., Calderone A., Perrault L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J. Pharmacol. Exp. Ther. 2008, 325:961-968.
90. Cantó C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
91. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
92. Sehmisch S., Hammer F., Christoffel J., Seidlova-Wuttke D., Tezval M., Wuttke W., Stuermer K.M., Stuermer E.K. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis. Planta Med. 2008, 74:794-801.
93. Bäckesjö C.M., Li Y., Lindgren U., Haldosén L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 2006, 21:993-1002.
94. Bäckesjö C.M., Li Y., Lindgren U., Haldosén L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009, 189:93-97.
95. Vu C.B., Bemis J.E., Disch J.S., Ng P.Y., Nunes J.J., Milne J.C., Carney D.P., Lynch A.V., Smith J.J., Lavu S., Lambert P.D., Gagne D.J., Jirousek M.R., Schenk S., Olefsky J.M., Perni R.B. Discovery of imidazo[1, 2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem. 2009, 52:1275-1283.
96. Bemis J.E., Vu C.B., Xie R., Nunes J.J., Ng P.Y., Disch J.S., Milne J.C., Carney D.P., Lynch A.V., Jin L., Smith J.J., Lavu S., Iffland A., Jirousek M.R., Perni R.B. Discovery of oxazolo[4, 5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg. Med. Chem. Lett. 2009, 19:2350-2353.
97. Nayagam V.M., Wang X., Tan Y.C., Poulsen A., Goh K.C., Ng T., Wang H., Song H.Y., Ni B., Entzeroth M., Stünkel W. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 2006, 11:959-967.
98. Yang H., Baur J.A., Chen A., Miller C., Adams J.K., Kisielewski A., Howitz K.T., Zipkin R.E., Sinclair D.A. Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 2007, 6:35-43.
99. Jaliffa C., Ameqrane I., Dansault A., Leemput J., Vieira V., Lacassagne E., Provost A., Bigot K., Masson C., Menasche M., Abitbol M. Sirt1 involvement in rd10 mouse retinal degeneration. Investig. Ophthalmol. Vis. Sci. 2009, 50:3562-3572.
100. Smith J.J., Kenney R.D., Gagne D.J., Frushour B.P., Ladd W., Galonek H.L., Israelian K., Song J., Razvadauskaite G., Lynch A.V., Carney D.P., Johnson R.J., Lavu S., Iffland A., Elliott P.J., Lambert P.D., Elliston K.O., Jirousek M.R., Milne J.C., Boss O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol. 2009, 3:31.
101. Shindler K.S., Ventura E., Rex T.S., Elliott P., Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Investig. Ophthalmol. Vis. Sci. 2007, 48:3602-3609.
102. Yamazaki Y., Usui I., Kanatani Y., Matsuya Y., Tsuneyama K., Fujisaka S., Bukhari A., Suzuki H., Senda S., Imanishi S., Hirata K., Ishiki M., Hayashi R., Urakaze M., Nemoto H., Kobayashi M., Tobe K. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am. J. Physiol. Endocrinol. Metab. 2009, 1.
103. Mai A., Valente S., Meade S., Carafa V., Tardugno M., Nebbioso A., Galmozzi A., Mitro N., De Fabiani E., Altucci L., Kazantsev A. Study of 1, 4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J. Med. Chem. 2009, 52:5496-5504.
104. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.